Your browser doesn't support javascript.
Diagnosis and treatment of thrombotic microangiopathy.
Thompson, Gemma L; Kavanagh, David.
  • Thompson GL; Complement Therapeutics Research Group, Translational and Clinical Research Institute, Newcastle University, Newcastle upon Tyne, UK.
  • Kavanagh D; National Renal Complement Therapeutics Centre, Royal Victoria Infirmary, Newcastle upon Tyne, UK.
Int J Lab Hematol ; 44 Suppl 1: 101-113, 2022 Sep.
Article in English | MEDLINE | ID: covidwho-2063738
ABSTRACT
Thrombotic microangiopathy (TMA) is characterized by thrombocytopenia, microangiopathic haemolytic anaemia and end organ damage. TMAs have varying underlying pathophysiology and can therefore present with an array of clinical presentations. Renal involvement is common as the kidney is particularly susceptible to the endothelial damage and microvascular occlusion. TMAs require rapid assessment, diagnosis, and commencement of appropriate treatment due to the high morbidity and mortality associated with them. Ground-breaking research into the pathogenesis of TMAs over the past 20 years has driven the successful development of targeted therapeutics revolutionizing patient outcomes. This review outlines the clinical presentations, pathogenesis, diagnostic tests and treatments for TMAs.
Subject(s)
Keywords

Full text: Available Collection: International databases Database: MEDLINE Main subject: Thrombotic Microangiopathies Type of study: Diagnostic study / Prognostic study Limits: Humans Language: English Journal: Int J Lab Hematol Journal subject: Hematology Year: 2022 Document Type: Article Affiliation country: Ijlh.13954

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Main subject: Thrombotic Microangiopathies Type of study: Diagnostic study / Prognostic study Limits: Humans Language: English Journal: Int J Lab Hematol Journal subject: Hematology Year: 2022 Document Type: Article Affiliation country: Ijlh.13954